Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
12.85
Nov 17 • 3:59 PM ET Dollar change-0.07 Percentage change(-0.54%)
Aftermarket Close
12.85
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
172.13M
Enterprise Value
153.32M
Income
-1.77M
Sales
123.43M
Book/sh
10.27
Cash/sh
3.36
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
235
IPO
May 03, 1993
P/E
-
Forward P/E
12.85
PEG
0.11
P/S
1.39
P/B
1.25
P/C
3.83
P/FCF
75.17
EV/EBITDA
49.94
EV/Sales
1.24
Quick Ratio
2.72
Current Ratio
3.86
Debt/Eq
0.19
LT Debt/Eq
0.18
Option/Short
Yes / Yes
EPS (ttm)
-0.14
EPS next Y
1.00
EPS next Q
0.13
EPS this Y
909.09%
EPS next Y
-9.91%
EPS next 5Y
118.66%
EPS past 3/5Y
9.40% 14.76%
Sales past 3/5Y
-10.28% -2.86%
EPS Y/Y TTM
94.37%
Sales Y/Y TTM
9.42%
EPS Q/Q
85.63%
Sales Q/Q
9.98%
Insider Own
6.28%
Insider Trans
0.24%
Inst Own
90.51%
Inst Trans
-1.42%
ROA
-0.14%
ROE
-0.18%
ROIC
-1.09%
Gross Margin
63.40%
Oper. Margin
-2.11%
Profit Margin
-1.43%
SMA20
-28.24%
SMA50
-33.54%
SMA200
-21.91%
Trades
Shs Outstand
13.39M
Shs Float
12.55M
52W High
22.88 -43.84%
52W Low
9.01 42.62%
Volatility
5.43% 6.35%
ATR (14)
1.09
RSI (14)
22.26
Beta
0.30
Rel Volume
1.33
Avg Volume
106.31K
Volume
140,946
Perf Week
-4.60%
Perf Month
-36.45%
Perf Quarter
-39.56%
Perf Half Y
-13.29%
Perf YTD
33.71%
Perf Year
33.16%
Perf 3Y
-38.81%
Perf 5Y
-67.69%
Perf 10Y
-71.50%
Prev Close
12.92
Price
12.85
Change %
-0.54%
Consensus
Strong Buy
Avg. Price Target
$20.00
Implied Upside
+55.6%
Analysts7incl. previous ratings
Rating Distribution4 Buy · 2 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 18, 2026Resumed
RILY logoRB. Riley Securities
Buy$23+79.0%
Apr 17, 2025Initiated
RILY logoRB. Riley Securities
Buy$21+63.4%
Nov 01, 2024Reiterated
BBarrington Research
Outperform$37 → $25+94.6%
Aug 14, 2023Upgrade
BBarrington Research
Mkt Perform → Outperform$24+86.8%
Mar 07, 2023Downgrade
BBarrington Research
Outperform → Mkt Perform
Nov 09, 2022Upgrade
BBarrington Research
Mkt Perform → Outperform$31+141.2%
Oct 14, 2022Resumed
SStephens
Equal-Weight$26+102.3%
Mar 09, 2022Downgrade
SStephens
Overweight → Equal-Weight$35+172.4%
Mar 09, 2022Downgrade
BBarrington Research
Outperform → Mkt Perform
Nov 16, 2021Initiated
SStephens
Overweight$55+328.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jellison William RFormer DirectorAug 07 '26Proposed Sale21.0716,864355,255Aug 07 05:28 PM
Fischetti Gary PDirectorAug 03 '26Buy20.751,00020,74553,015Aug 05 04:30 PM
Fischetti Gary PDirectorAug 04 '26Buy20.321,00020,31554,015Aug 05 04:30 PM
HENNEMAN JOHN B IIIDirectorMay 01 '26Buy14.665,00073,32054,871May 04 08:34 AM
Griffin Stephen D.President and CEOApr 30 '26Buy12.2912,200149,88136,163Apr 30 05:22 PM
Anika Therapeutics, Inc. engages in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.
Executive ChairDr. Cheryl Renee Blanchard Ph.D.
PresidentMr. Stephen D. Griffin
Senior VPMr. Ian W. McLeod
Executive Director of Corporate Development & Investor RelationsMr. Matthew Hall
VP & Chief Human Resources OfficerMs. Lisa Funiciello